Table 1.
Patient characteristics
| All (n=46) |
Stable atherosclerosis (n=27) |
Unstable atherosclerosis (n=19) |
P value* | |
| Age (years) | 67 (60–74) | 69 (66–74) | 60 (51–70) | 0.01 |
| Male sex | 34 (74) | 20 (74) | 14 (74) | 0.97 |
| BMI (kg/m2) | 28 (25–31) | 28 (24–30) | 27 (25–32) | 0.39 |
| Systolic BP (mm Hg) | 140 (124–160) | 149 (134–167) | 125 (114–139) | <0.001 |
| 18F-Fluciclatide dose (MBq) | 229 (217–237) | 228 (217–236) | 229 (215–240) | 0.69 |
| Cardiovascular history | ||||
| Angiographically documented CAD | 26 (57) | 7 (26) | 19 (100) | <0.001 |
| Prev MI | 24 (52) | 5 (19) | 19 (100) | <0.001 |
| Prev PCI | 20 (43) | 2 (7) | 18 (95) | <0.001 |
| Prev CVD | 4 (11) | 4 (14) | 0 (0) | 0.08 |
| Risk factors | ||||
| Current smoker | 9 (20) | 1 (4) | 8 (42) | 0.001 |
| Diabetes mellitus | 6 (13) | 4 (14) | 2 (10) | 0.58 |
| Prior hypertension | 23 (50) | 18 (67) | 6 (32) | 0.02 |
| Prior hypercholesterolaemia | 25 (54) | 12 (44) | 12 (63) | 0.21 |
| hs-CRP (mg/L) | 3.5 (1.4–7.8) | 2.7 (1.4–5.8) | 5.6 (2.0–11.7) | 0.08 |
| Medications | ||||
| Aspirin | 28 (61) | 10 (37) | 19 (100) | <0.001 |
| Clopidogrel | 19 (41) | 4 (14) | 19 (100) | <0.001 |
| Statin | 31 (67) | 13 (48) | 19 (100) | <0.001 |
| β-Blocker | 27 (59) | 8 (30) | 19 (100) | <0.001 |
| ACEi/ARB | 31 (67) | 10 (37) | 18 (95) | <0.001 |
| Calcium channel blocker | 7 (15) | 6 (22) | 1 (5) | 0.11 |
Categorical data are displayed as n (%).
Continuous data are displayed as median (IQR).
*P values are quoted for comparisons between matched stable and unstable groups.
ACEi, ACE-inhibitor; ARB, angiotensin receptor blocker; AS, aortic stenosis; BMI, body mass index; BP, blood pressure; CAD, coronary artery disease; CVD, cerebrovascular disease; IHD, ischaemic heart disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; hs-CRP, high-sensitivity C reactive protein.